DNA GINKGO BIOWORKS HOLDINGS INC revenue, earnings and financials

For the quarter ended June 30, 2026, GINKGO BIOWORKS HOLDINGS INC reported revenue of $20.2M (down 48.5% from a year earlier), net income of −$46.7M and diluted EPS of n/a; over the last four quarters revenue was $132M and net income $21.6M; for the fiscal year ended December 2025 revenue was $170M, down 25.1% on the year before.

DNA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $170M, gross profit n/a, operating income −$315M, net income −$313K (margin -0.2%), EPS −$5.64
• Fiscal year ended Dec 2024: revenue $227M, gross profit n/a, operating income −$560M, net income −$547K (margin -0.2%), EPS −$10.54
• Fiscal year ended Dec 2023: revenue $251M, gross profit n/a, operating income −$864M, net income −$893K (margin -0.4%), EPS −$18.37
• Fiscal year ended Dec 2022: revenue $478M, gross profit n/a, operating income −$2.21B, net income −$2.11M (margin -0.4%), EPS −$50.20
• Fiscal year ended Dec 2021: revenue $314M, gross profit n/a, operating income −$1.83B, net income −$1.83M (margin -0.6%), EPS −$1.39

DNA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $20.2M (down 48.5% year over year), net income −$46.7M, EPS n/a
• Quarter ended Mar 31, 2026: revenue $19.5M (down 49.1% year over year), net income −$82.6M, EPS n/a
• Quarter ended Dec 31, 2025 (from the annual report): revenue $54.0M (up 23.1% year over year), net income $232M, EPS −$1.41
• Quarter ended Sep 30, 2025: revenue $38.8M (down 56.4% year over year), net income −$80.8M, EPS −$1.45
• Quarter ended Jun 30, 2025: revenue $39.1M (down 30.4% year over year), net income −$60.3M, EPS −$1.10
• Quarter ended Mar 31, 2025: revenue $38.2M (up 0.8% year over year), net income −$91.0M, EPS −$1.68
• Quarter ended Dec 31, 2024 (from the annual report): revenue $43.8M (up 26.2% year over year), net income $439M, EPS −$1.91
• Quarter ended Sep 30, 2024: revenue $89.0M (up 60.6% year over year), net income −$56.4M, EPS −$1.08
• Quarter ended Jun 30, 2024: revenue $56.2M (down 30.2% year over year), net income −$217M, EPS −$4.23
• Quarter ended Mar 31, 2024: revenue $37.9M (down 53.0% year over year), net income −$166M, EPS −$3.32
• Quarter ended Dec 31, 2023 (from the annual report): revenue $34.8M (down 64.6% year over year), net income $680M, EPS −$11.96
• Quarter ended Sep 30, 2023: revenue $55.4M (down 16.5% year over year), net income −$303M, EPS −$6.21
• Quarter ended Jun 30, 2023: revenue $80.6M (down 44.3% year over year), net income −$173M, EPS −$0.09
• Quarter ended Mar 31, 2023: revenue $80.7M (down 52.1% year over year), net income −$205M, EPS −$0.11
• Quarter ended Dec 31, 2022 (from the annual report): revenue $98.3M (down 33.8% year over year), net income $1.93B, EPS −$49.01
• Quarter ended Sep 30, 2022: revenue $66.4M (down 14.4% year over year), net income −$670M, EPS −$0.41
• Quarter ended Jun 30, 2022: revenue $145M (up 231.4% year over year), net income −$669M, EPS −$0.41
• Quarter ended Mar 31, 2022: revenue $168M (up 281.9% year over year), net income −$591M, EPS −$0.37
• Quarter ended Dec 31, 2021 (from the annual report): revenue $148M, net income $228M, EPS n/a
• Quarter ended Sep 30, 2021: revenue $77.6M, net income −$102M, EPS −$0.08

DNA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$171M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$320M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$296M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$252M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$254M, share buybacks n/a

DNA balance sheet

• Jun 30, 2026: cash $84.5M, total assets $990M, total liabilities $570M, shareholders' equity $420M
• Mar 31, 2026: cash $144M, total assets $1.03B, total liabilities $590M, shareholders' equity $443M
• Dec 31, 2025: cash $167M, total assets $1.12B, total liabilities $611M, shareholders' equity $509M
• Sep 30, 2025: cash $111M, total assets $1.19B, total liabilities $629M, shareholders' equity $560M
• Jun 30, 2025: cash $204M, total assets $1.23B, total liabilities $618M, shareholders' equity $613M
• Mar 31, 2025: cash $312M, total assets $1.29B, total liabilities $646M, shareholders' equity $647M
• Dec 31, 2024: cash $562M, total assets $1.38B, total liabilities $661M, shareholders' equity $716M
• Sep 30, 2024: cash $616M, total assets $1.48B, total liabilities $683M, shareholders' equity $798M

What is DNA's revenue?

GINKGO BIOWORKS HOLDINGS INC reported $132M of revenue over its last four quarters, through June 30, 2026.

Is DNA profitable?

Yes. GINKGO BIOWORKS HOLDINGS INC earned $21.6M over the last four quarters.

DNA ownership and insider trades · All stocks